Strategic Partnerships Recent high-profile collaborations with Merck and Keytruda (pembrolizumab) indicate ImmunOs is actively pursuing combination therapies to enhance efficacy. This suggests a sales opportunity to position complementary biologics, immunomodulatory agents, or diagnostic tools that can support combination regimens and clinical trial design.

Financing Momentum A USD 11 million Series C close in 2024 signals investor confidence and a runway for continued clinical development. Leverage this to explore partnerships around late-stage translational services, CRO partnerships, or co-development arrangements to accelerate IOS-1002 programs and expand the pipeline.

Lead Program Focus IOS-1002 is ImmunOs’ lead program advancing to Phase 1 and aimed at LILRB receptor modulation with potential for monotherapy and checkpoint inhibitor combinations. Sales opportunities exist for contract development, manufacturing, and analytics services to support clinical-grade production and regulatory filing needs.

Clinical Collaboration Strategic clinical collaborations with major players highlight a receptiveness to external expertise and resource sharing. This creates openings for advisory, co-development, and platform technology collaborations that can extend reach into additional tumor types or autoimmune indications.

Manufacturing Capacity Partnerships with ProBioGen for large-scale manufacturing of IOS-1002 demonstrate readiness to scale. This opens doors for ongoing CMOs, supply chain optimization, and manufacturing services opportunities as the program progresses through trials and potential commercialization.